Table 2.

Comparison of baseline characteristics of patients from the LUNAR trial treated with rituximab who achieved complete peripheral depletion versus those who never achieved complete peripheral depletion

CharacteristicsComplete Peripheral Depletion, n=53Incomplete Peripheral Depletion, n=15
Age, yr, mean±SD32±831±10
Women48 (90%)11 (73%)
Duration of lupus nephritis, mo, median (range)10.5 (0.4–210)17.8 (0.4–130)
Race
 White15 (28%)4 (26%)
 Hispanic21 (39%)6 (41%)
 Black15 (28%)4 (26%)
 Asian2 (4%)1 (7%)
Biopsy class
 Class III only6 (11%)2 (13%)
 Class III and V11 (21%)5 (33%)
 Class IV only28 (53%)7 (47%)
 Class IV and V8 (15%)1 (7%)
Baseline CD19, cells/μl, median (range)166 (11–1477)106 (20–1839)
Creatinine, mg/dl, mean±SD 0.95±0.41.17±0.5
eGFR, ml/min, mean±SD79±3358±24
Urine protein/creatinine ratio, mg/mg, mean±SD 3.3±2.35.2±2.45
Albumin, g/dL, mean±SD2.8±0.672.1±0.87
Nephrotic syndrome present15 (28%)11 (73%)
IgG, g/L, median (range)9.9 (3.4–22)7.7 (1.2–20)
C3, mg/dl, median (range)69 (23–151)59 (32–130)
C4, mg/dl, median (range)13 (5–42)9.5 (5–24)
Anti-dsDNA positivity42 (80%)13 (87%)
Anti-Smith positivity17 (32%)1 (7%)
BAFF levels, ng/ml, median (range)3.1 (0.1–19)3.5 (1.4–24)
Peak rituximab levels, μg/ml, median (range)456 (290–1070)386 (293–565)
  • LUNAR, the Lupus Nephritis Assessment with Rituximab study; dsDNA, double-stranded DNA; BAFF, B cell activating factor.